HEALTH BRIEF: dengue surges, bird-flu vigilance, malaria vaccines scale up, and overdose prevention expands

Global health officials are ending October with a mixed dashboard: mosquito-borne disease is cresting in the tropics, avian influenza remains a low but persistent zoonotic risk, childhood malaria shots are moving from pilots to routine use, and harm-reduction tools for opioid overdoses continue to widen community access. The signal underneath the headlines is steady: prevention works when access is timely, and surveillance stays honest about remaining gaps.

Dengue first. WHO reports that from January through July 2025, countries notified over four million cases and more than three thousand deaths—spanning 97 countries this year. The agency warns climate variability, rapid urbanisation, and household water storage are expanding vector habitats, pushing outbreaks into places with little historical experience. Health ministries are scaling up mosquito control, early clinical triage and neighbourhood clean-ups ahead of the southern-hemisphere rainy season.

Avian influenza next. U.S. authorities continue to track H5N1 detections in dairy cattle and sporadic infections among exposed workers. CDC still assesses the public risk as low, while urging strict farm biosecurity and protective equipment for people handling sick birds or cows. Nevada’s February human case in a dairy employee—and reports of a second cattle-circulating genotype this year—underline that vigilance, not panic, is the prudent posture for health systems and food-safety regulators.

There is brighter news on malaria. WHO says the rollout of the RTS,S and R21/Matrix-M vaccines is well underway; by early April, 19 countries had introduced doses sub-nationally as part of routine immunisation, with more expansions slated through 2025. This month, Zambia became the 24th country to adopt a malaria vaccine, receiving 532,200 doses via UNICEF and Gavi. Modelling suggests thousands of young lives could be saved each year as coverage grows, especially when paired with testing, treatment and nets.

On overdose prevention, regulators and researchers are tracking how over-the-counter naloxone changes access. The FDA’s move to allow Narcan to be sold without a prescription opened pharmacy shelves nationally; recent RAND analysis finds availability rising but still uneven by price and location—keeping community distribution programs essential. Public-health departments stress that broad training on recognising overdose and promptly spraying naloxone remains the fastest way to prevent avoidable deaths.

Zooming out, WHO’s 2025 World Health Statistics recap the pandemic’s aftershocks on longevity and service coverage, while underscoring long-term gains that are not yet even. Global life expectancy rose by more than six years from 2000 to 2019, but healthy life expectancy climbed less—meaning people are living longer with more years affected by illness or disability. The message for planners is simple: invest simultaneously in prevention, primary care and rehabilitation—not only in acute treatment.

What to watch next: whether dengue peaks retreat as seasonal control intensifies; whether H5N1 biosecurity and worker protections blunt spillover to people; how quickly malaria-vaccine supply chains meet demand across Africa; and whether insurers, pharmacies and local governments keep driving down the out-of-pocket price of naloxone. As ever, the through-line is access—because speed, proximity and trust decide outcomes long before the ambulance arrives.

About The Author

S Arefin

See author's posts